Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy-Reference-Cited by-同舟云学术

Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy

Published:2020-09 Issue:1 Volume:108 Page:93-103
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Tormoen Garth W.,Blair Tiffany C.,Bambina Shelly,Kramer Gwen,Baird Jason,Rahmani Ramtin,Holland John M.,McCarty Owen J.T.,Baine Michael J.,Verma Vivek,Nabavizadeh Nima,Gough Michael J.,Crittenden Marka

Funder

National Institutes of Health

Radiological Society of North America

NIH

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference37 articles.

1. Immune system plays an important role in the success and failure of conventional cancer therapy;Gough;Immunotherapy,2012

2. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment;Lee;Blood,2009

3. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer;Demaria;Clin Cancer Res,2005

4. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment;Vanpouille-Box;Vaccine,2015

5. Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: Outcomes, toxicities, and low-dose radiation-related abscopal responses;Welsh;Cancer Immunol Res,2019

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hallmarks of pancreatic cancer: spotlight on TAM receptors;eBioMedicine;2024-09

2. In the Eyes of the Beholder—New Mertk Knockout Mouse and Re-Evaluation of Phagocytosis versus Anti-Inflammatory Functions of MERTK;International Journal of Molecular Sciences;2024-05-13

3. Potential roles for efferocytosis in glioblastoma immune evasion;Neuro-Oncology Advances;2024-01-01

4. Efferocytosis: An accomplice of cancer immune escape;Biomedicine & Pharmacotherapy;2023-11

5. Challenges and opportunities in the development of combination immunotherapy with OX40 agonists;Expert Opinion on Biological Therapy;2023-08-20